Cargando…
B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design
B cells are believed to be central to the disease process in systemic lupus erythematosus (SLE), making them a target for new therapeutic intervention. In recent years there have been many publications regarding the experience in SLE of B-cell depletion utilising rituximab, an anti-CD20 mAb that tem...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3624107/ https://www.ncbi.nlm.nih.gov/pubmed/23566295 http://dx.doi.org/10.1186/ar3910 |